14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LSCP vs ELAB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ELAB Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 5–3 Matrix Metrics)
ELAB Overall Winner
6-Pillar Tally: LSCP 0 – 3 ELAB (3 Tie)
Matrix Metrics: LSCP 3 – 5 ELAB
As of Nov 20, 2026, PMGC Holdings Inc. (ELAB) is the stronger overall head-to-head candidate over LSCP (LSCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LSCP carries a Unified Composite Score of 54.1/100 (HOLD) at $24.25 (N/M Forward P/E, N/A operating margin), whereas ELAB carries 40.9/100 (SELL) at $1.14 (N/M Forward P/E, -470.0% operating margin).
Composite vs. Pillar Nuance: While LSCP currently prints a higher short-term Unified Composite Score (54.1/100 HOLD vs. ELAB 40.9/100 SELL), ELAB captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-470.0% vs. N/A operating margin) and revenue trajectory (-45.8% vs. N/A YoY).
Technical & Structure Timing Caution: LSCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 54.3); meanwhile ELAB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LSCP vs ELAB. Trailing 12-month operating profitability (LSCP N/A vs ELAB -470.0%) and valuation multiples (LSCP N/M vs ELAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ELAB Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5M market capitalization and -470.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LSCP vs ELAB Key Questions & Quantitative Answers
As of Nov 20, 2026, PMGC Holdings Inc. (ELAB) is the stronger overall head-to-head candidate over LSCP (LSCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LSCP carries a Unified Composite Score of 54.1/100 (HOLD) at $24.25 (N/M Forward P/E, N/A operating margin), whereas ELAB carries 40.9/100 (SELL) at $1.14 (N/M Forward P/E, -470.0% operating margin). Composite vs. Pillar Nuance: While LSCP currently prints a higher short-term Unified Composite Score (54.1/100 HOLD vs. ELAB 40.9/100 SELL), ELAB captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-470.0% vs. N/A operating margin) and revenue trajectory (-45.8% vs. N/A YoY). Technical & Structure Timing Caution: LSCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 54.3); meanwhile ELAB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ELAB leads the Growth & Scale pillar: LSCP posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ELAB at -45.8% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (-20.5% gross margin, -470.0% operating margin). On trailing 12-month operating scale, LSCP generates N/A in USD-normalized revenue versus $2.6M for ELAB. In operating R&D and SG&A reinvestment, LSCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ELAB.
LSCP and ELAB trade at balanced relative valuation multiples. LSCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ELAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LSCP (N/A ROE) versus ELAB (-105.2% ROE) capital efficiency.
In options market volatility and institutional positioning, LSCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 4% Vol realized risk). By comparison, ELAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.62β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.